Patent intelligence · US
US 8329744
Methods of preventing the serotonin syndrome and compositions for use thereof
Methods of preventing the serotonin syndrome and compositions for use thereof
Patent details — US 8329744
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 11, 2012
- Expiration
- Dec 6, 2032
- Applicant
- Relmada Therapeutics, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/34, A61K45/06
Quick answer
US 8329744 (Methods of preventing the serotonin syndrome and compositions for use thereof) is held by Relmada Therapeutics, Inc.. Status: granted. Granted Dec 11, 2012. Expires Dec 6, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Relmada Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/34, A61K45/06
More from Relmada Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11607407
Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use
granted -
US 10624887
Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol
granted -
US 9855226
d-methadone for the treatment of psychiatric symptoms
granted -
US 9468611
d-Methadone for the treatment of psychiatric symptoms
granted -
US 9364430
Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
granted -
US 9125833
Multimodal abuse resistant and extended release opioid formulations
granted
Related coverage
Frequently asked questions
What is US patent 8329744?
US 8329744 (Methods of preventing the serotonin syndrome and compositions for use thereof) is held by Relmada Therapeutics, Inc.. Status: granted. Granted Dec 11, 2012. Expires Dec 6, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8329744?
Relmada Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 8329744 expire?
Our index shows an expiration date of Dec 6, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.